Nixon, A., Liu, J., Xiong, N., Hurwitz, H. I., Lyu, J., Liu, Y., … Secord, A. A. (2021). Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial. In GYNECOLOGIC ONCOLOGY (Vol. 162, pp. S99–S99).

Nixon, Andrew, Joyce Liu, Niya Xiong, Herbert I. Hurwitz, Jing Lyu, Yingmiao Liu, Mark Starr, et al. “Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial.” In GYNECOLOGIC ONCOLOGY, 162:S99–S99, 2021.

Nixon A, Liu J, Xiong N, Hurwitz HI, Lyu J, Liu Y, et al. Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial. In: GYNECOLOGIC ONCOLOGY. 2021. p. S99–S99.

Nixon, Andrew, et al. “Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial.” GYNECOLOGIC ONCOLOGY, vol. 162, 2021, pp. S99–S99.

Nixon A, Liu J, Xiong N, Hurwitz HI, Lyu J, Liu Y, Starr M, Brady J, Swisher E, Owzar K, Wenham R, Hendrickson AW, Armstrong D, Chan N, Cohn D, Lee J-M, Penson R, Cristea M, Gaillard S, Abbruzzese J, Matsuo K, Olawaiye A, Kohn E, Ivy P, Secord AA. Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial. GYNECOLOGIC ONCOLOGY. 2021. p. S99–S99.